Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Posted by George Bondi on Sep 27th, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $41.67.

PBLS has been the topic of several recent analyst reports. Zacks Research raised Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Lifesci Capital upgraded Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Bank of America started coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $45.00 price objective on the stock. Weiss Ratings raised shares of Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 18th. Finally, Evercore initiated coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They issued an “outperform” rating for the company.

Get Our Latest Stock Analysis on Parabilis Medicines

Parabilis Medicines Stock Performance

Shares of PBLS stock opened at $31.20 on Friday. The business’s fifty day simple moving average is $36.38. Parabilis Medicines has a 12-month low of $24.51 and a 12-month high of $42.49.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. On average, analysts predict that Parabilis Medicines will post -2.05 earnings per share for the current year.

Institutional Investors Weigh In On Parabilis Medicines

Several institutional investors and hedge funds have recently made changes to their positions in PBLS. WINTON GROUP Ltd purchased a new stake in shares of Parabilis Medicines during the second quarter valued at $955,000. Squarepoint Ops LLC purchased a new position in Parabilis Medicines in the 2nd quarter worth $1,327,000. Frazier Life Sciences Management L.P. purchased a new position in Parabilis Medicines in the 2nd quarter worth $52,572,000. ICONIQ Capital LLC acquired a new stake in Parabilis Medicines during the 2nd quarter worth about $9,580,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Parabilis Medicines during the 2nd quarter worth about $274,000.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.